Not connected to GLP3Planner: GLP3Planner has no connection to “GLP3-B” capsules or any shop selling them through social media ads. We don't sell medication, supplements or peptides and never take orders. For an order or refund, contact the seller or your bank or card provider.

Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #triumph trials Clear filter

Educational Content

View all →
Showing 3 of 3 articles
No articles found matching your search. Try a different term or view all articles.

Is Retatrutide FDA Approved? Status, Trials & Timeline (2026)

Retatrutide is not FDA-approved. Lilly is reported to plan an FDA filing in early 2027, and a decision in late 2027 or 2028 is our estimate, not Lilly's. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

When Will Retatrutide Be FDA Approved? Timeline, Trials & Projections (2026)

A current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans an FDA filing in early 2027, and FDA's usual review times would put a decision in late 2027 or 2028 (our estimate, not Lilly's). Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.

How to Get Retatrutide: Clinical Trials and Expanded Access Are the Only Lawful Routes

Retatrutide isn't FDA-approved yet. Lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). This guide covers how to join a trial, who qualifies for expanded access, why compounding pharmacies cannot lawfully supply retatrutide, and what research peptide vendors actually sell, plus what you need to know about safety, legality, and costs.